Scottish 1nhaler raises £2.2 million to develop cardboard inhaler
The funding will support clinical trial preparations for its asthma product, with a regulatory filing targeted for late 2027.
Scotland-based device developer 1nhaler has raised £2.2 million in follow-on investment to advance a cardboard inhaler towards its first regulatory approval. Archangels headed the round, joined by Scottish Enterprise and BBB Investments. The company's lead product, 1nhaler Salbutamol, pairs the device with salbutamol, an established asthma medicine.
The company said the money would fund the completion of a transfer to contract manufacturing, allowing material for clinical trials to be produced. It will also support a small clinical trial intended to underpin a regulatory filing, which the company is targeting for late 2027.
Made mainly of cardboard, the single-dose dry powder inhaler has a credit-card-sized format that opens into a three-dimensional device. It contains few components, including a patented membrane-based system. According to 1nhaler, the design aims to make large-scale manufacturing simpler and less costly, while addressing accessibility and environmental limitations of existing inhalers.
Part of the investment will pay for an engineering study with Harro Höfliger on scaling up commercial production. It will also support discussions with potential partners about the platform and its lead product. Beyond respiratory treatments, the company says the platform could be used for dry powder medicines including pain relief and vaccines.
